Ovarian cancer is the fifth most common cause of death from all cancers among women in the world and has the highest mortality rate of the gynaecological cancers ([@bib6]). Overall, ovarian cancer has the worst prognosis of all gynaecological cancers, with a 5-year survival rate of \<40% ([@bib3]). Surgical resection is the most effective and potentially curative therapy; however, most ovarian cancers are diagnosed at a late stage when the metastasis has already occurred ([@bib5]). Under this scenario, chemotherapy is considered an option, but it provides only a modest improvement in patient survival ([@bib23]). Therefore, developing novel and effective therapeutic strategies against ovarian cancer is urgently needed.

Cisplatin (cis-diaminodichloroplatinum, CDDP) is a metal-based anti-cancer drug that has been used extensively over the past four decades for the treatment of several types of cancers ([@bib25]), including ovarian cancer. However, most patients do not respond well to CDDP treatment and those who respond eventually develop chemoresistance and exhibit cancer progression ([@bib16]). It is implied that cellular resistance to cisplatin is either inherent or acquired during the treatment; however, the underlying molecular mechanisms are still not well-established.

The role of platelet-activating factor (PAF)/platelet-activating factor receptor (PAFR) in tumours has been investigated in recent years. The PAF/PAFR axis is involved in oncogenic transformation ([@bib15]), anti-apoptosis ([@bib10]), metastasis ([@bib19]) and angiogenesis ([@bib8]) in several types of cancers. We demonstrated that PAF--PAFR is commonly activated in non-mucinous ovarian cancer cells ([@bib1]). A phospholipid mediator, PAF, can activate PAFR and promote ovarian cancer cell proliferation and invasion ([@bib13]). Recent experiments have also revealed an important role of PAF--PAFR in chemotherapy, demonstrating that PAFR activation can augment cytokine production induced by chemotherapy through a mechanism dependent on nuclear factor-kappa B (NF-*κ*B) ([@bib7]). In this scenario, specific PAFR antagonists may have a potentiating effect in enhancing the CDDP sensitivity of ovarian cancer cells.

In this study, we examined the effect of cisplatin on PAFR expression in ovarian cancer cells to explore the possibility of a counter-defence mechanism. We demonstrated, for the first time, that cisplatin induces dose- and time-dependent upregulation of PAFR in ovarian cancer cells. The nuclear accumulation of NF-*κ*B and hypoxia inducible factor-1 alpha (HIF-1*α*) is caused by CDDP, however, the silencing of these two transcription factors by RNA interference attenuates the CDDP-induced PAFR upregulation. We also showed that CDDP-induced PAFR expression induces the activation of the phosphoinositide 3-kinase (PI3K) and extracellular signal-regulated kinase (ERK) pathways; however, the simultaneous blockade of PI3K and ERK further sensitises ovarian cancer cells to CDDP. Furthermore, our data reveal that the PAFR-specific antagonist Ginkgolide B (GB) inhibits tumour growth in a SKOV-3-luc ovarian cancer model, reducing tumour progression when combined with cisplatin. Together, our results indicate that the expression of PAFR modulates the cisplatin sensitivity of ovarian cancer cells and is a novel target for combined therapy.

Materials and Methods
=====================

Cell culture and chemical reagents
----------------------------------

The ovarian cancer cell lines SKOV-3 and CAOV-3 (purchased from the Cell Bank of the Chinese Academy of Science, Shanghai, China) were cultured at 37 °C in a humidified 5% CO~2~ atmosphere in RPMI-1640 medium with 10% foetal calf serum (Gibco, Invitrogen, Carlsbad, CA, USA), 100 IU ml^−1^ penicillin G, and 100 mg ml^−1^streptomycin sulphate (Sigma-Aldrich, St Louis, MO, USA). Lipofectamine 2000 Transfection Reagent and Opti-MEM-1 Medium (Invitrogen) were used for siRNA transfection. The siRNA was synthesised by Shanghai GenePharma Co (Shanghai, China). Cis-diaminodichloroplatinum, WEB2086 (PAFR antagonist) and GB (\>90% high-performance liquid chromatography grade) were purchased from Sigma-Aldrich. PD98059 (ERK inhibitor) and LY294002 (PI3K inhibitor) were obtained from Cell Signaling Technology (Boston, MA, USA). A Cell Counting Kit8 (CCK-8) was purchased from Dojindo Molecular Technologies Inc. (Kumamoto, Japan) and the Alexa Fluor 488 annexin V/Dead Cell Apoptosis Kit was from Invitrogen. The rabbit polyclonal antibodies used in this study were directed against PAFR (Abcam, HongKong, China), NF-*κ*B (Cell Signaling Technology), HIF-1*α* (Cell Signaling Technology), Histone H3 (Cell Signaling Technology), phospho-P70S6K (Cell Signaling Technology), phospho-AKT and phospho-ERK (Cell Signaling Technology). The mouse monoclonal antibodies used in this study were directed against actin and tubulin (Sigma, St Louis, MO, USA).

Quantitative real-time PCR
--------------------------

Real-time PCR analyses were performed with SYBR premix Ex Taq (TaKaRa, Osaka, Japan) on a 7900 Real-time PCR system (Applied Biosystems Inc., Foster, CA, USA). The primer sequences used for PAFR detection were as follows: sense-5′-GACAGCATAGAGGCTGAGGC-3′ and antisense-5′-TAGCCATTAGCAATGACCCC-3′. The 18 s rRNA used for normalisation was as follows: sense-5′-GTAACCCGTTGAACCCCATT-3′ and antisense-5′-CCATCCAATCGGTAGTAGCG-3′. The ΔCT method was used to obtain the relative expression value of PAFR compared with the 18 s rRNA amplification.

Transfection of SiRNA
---------------------

For the specific knockdown of PAFR, NF-*κ*B and HIF-1*α*, cells were cultured in six-well plates and transiently transfected with 50 n[M]{.smallcaps} of non-target or target-specific siRNAs using Lipofectamine 2000 according to the manufacturer\'s instructions.

Nuclear and cytoplasmic fractionation
-------------------------------------

The preparation of the cytoplasmic and nuclear extracts was performed using the Nuclear Extract Kit (Active Motif, Carlsbad, CA, USA) as described previously.

Western blot analysis
---------------------

Cellular extracts were prepared in a modified radioimmunoprecipitation assay buffer (50 mM Tris--HCl pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 m[M]{.smallcaps} EDTA, 1 m[M]{.smallcaps} PMSF, protease inhibitor cocktail). Protein concentrations of the cellular extracts were measured using a Bio-Rad protein assay kit (Hercules, CA, USA). Then, cellular extracts were subjected to SDS--PAGE. Proteins were transferred to PVDF membranes. After blocking for 1 h at room temperature in 5% BSA, blots were probed with a primary antibody at a 1 : 1000 dilution and incubated overnight at 4 °C. Subsequently, blots were washed three times and incubated for 1 h at room temperature with a 1 : 10000 dilution of the secondary peroxidase-conjugated antibodies. Following three washes, immunoreactive bands were detected using electrochemiluminescence.

Cell proliferation assay and apoptosis assay
--------------------------------------------

Cell proliferation was measured using a CCK-8 Assay, and cell apoptosis was detected using an Alexa Fluor 488 annexin V/Dead Cell Apoptosis Kit Assay. Both processes were conducted according to the manufacturer\'s protocols.

Immunofluorescence
------------------

The SKOV-3 cells with or without CDDP treatment were fixed with 100% methanol for 6 min at −20 °C, then washed with PBS and left at 4 °C until use. Cells were permeabilized by incubation in PBS containing 0.3% Triton X-100 and 5% goat serum for 30 min. A polyclonal antibody against NF-*κ*B and HIF-1*α* were used at a 1 : 100 dilution, and a secondary antibody FITC-conjugated goat anti-rabbit (Invitrogen, was used at a 1 : 200 dilution. The first antibody was incubated overnight at 4 °C and the second antibody for 2 h at RT. Images were captured with an Olympus DP 71 camera (Tokyo, Japan). The magnification level was 400 × .

Animals and treatments
----------------------

Female athymic nu/nu mice (4 to 6 weeks old) were obtained from the Laboratory Animal Center of the Shanghai Institutes for Biological Sciences of the Chinese Academy of Sciences. All animal studies were conducted strictly in accordance with protocols approved by the Ethics Committee for Animal Experimentation of Fudan University. To represent late stage ovarian cancer with abdominal metastasis, we used the SKOV-3-luc cells, which were transfected with a luciferase-expressing vector kindly donated by Dr Bin Ye from Harvard Medical School, Boston, MA, USA. We injected 2 × 10^6^ SKOV-3-luc cells intraperitoneally (i.p.) into the female nu/nu mice. Luciferase activity was visualised through imaging of whole bodies using the *in vivo* imaging system Lumina (Caliper Life Sciences, Hopkinton, MA, USA) as described previously with minor adaptations at various time points post injection of cells. Briefly, animals were anaesthetised using the isoflurane-anesthesia system, d-luciferin dissolved in PBS (150 mg kg^−1^; Caliper Life Science, Brussels, Belgium) was injected i.p. Animals were kept anaesthetised during the measurements, which were performed 5 min after the injection of [D]{.smallcaps}-luciferin. Bioluminescence imaging was acquired with a 10 cm field of view and an exposure time of 60 s. The colour scale limits were set automatically and the quantitative analysis of bioluminescence was performed by measuring the luminescence signal intensity using the region of interest (ROI) settings of the Living Image 3.2 software (Caliper Life Sciences, Hopkinton, MA, USA). The measurements of ROI are expressed in total flux of photons. When the ROI of tumour tissues reached around 1 × 10^9^, mice were randomly divided (10 mice per group) into the following four groups: DMSO vehicle control, GB-treated, CDDP-treated, or GB+CDDP-treated. The groups were treated with several different strategies. The GB-treated group was intraperitoneally injected with 100 *μ*l of 100 mg ml^−1^of GB once per day for 3 weeks and the CDDP-treated group was intraperitoneally injected with 5 mg kg^−1^ of CDDP once per week for 3 weeks. The progress of tumour was visualised every 3 days by *in vivo* imaging system since first dosage of therapy. Statistical analysis was performed by Kruskal--Wallis and subsequent individual comparisons were performed by a multiple comparisons test using PASW Statistics 18 (SPSS Inc., Chicago, IL, USA). After 3 weeks of treatment, all mice were killed and the tumours were excised and weighed.

Immunohistochemistry (IHC)
--------------------------

Immunohistochemical analysis was carried out for PAFR protein expression of ovarian cancer tissues in four treatment groups. Immunohistochemical analysis was performed using the EnVision/AP system (DakoCytomation, Carpinteria, CA, USA). This system used an anti-rabbit immunoglobulin conjugated to an alkaline phosphatase polymer (Labelled polymer-AP), which is revealed as a red stain after the addition of the Substrate--Chromogen solution. Slides were washed with deionized water and counterstained with hematoxylin and 5% ammonium hydroxide and mounted in Accergel (Accurate Chemical and Scientific Corp., Westbury, NY, USA). The image was recorded by a digital camera (Optronic, Goleta, CA, USA). Each subject had three independent readings by two investigators using a semi-quantitative scoring system: 0, absent or trace staining; 1, minimal staining; 2, moderate staining; or 3, strong staining.

Platelet-activating factor assay
--------------------------------

Tail vein blood was collected from the nu/nu mice in each group at the different time points and the PAF concentrations were measured using a specific enzyme immunoassay kit (Groundwork Biotechnology Diagnosticate, San Diego, CA, USA). The assay was performed according to the manufacturer\'s instructions. Production of PAF was evaluated in duplicate, and amounts were taken from a standard curve of PAF. The sensitivity of the assay allowed the detection of up to 15 pg ml^−1^. When necessary, the samples were diluted in the assay buffer.

Statistical analysis
--------------------

All experiments were performed at least three times. The data are expressed as the 'mean±s.d.\'. Wherever appropriate, the data were also subjected to unpaired two-tailed Student\'s *t*-tests. Differences were considered significant when *P*\<0.05.

Results
=======

Treatment with CDDP induces increased PAFR expression in ovarian cancer cells
-----------------------------------------------------------------------------

The effect of CDDP on PAFR expression was examined in two human ovarian cancer cell lines, SKOV-3 and CAOV-3. After treatment with CDDP (0--60 *μ*[M]{.smallcaps}) for 24 h, we observed a dose-dependent increase in the expression of PAFR mRNA and protein levels in both cell lines ([Figure 1A and B](#fig1){ref-type="fig"}, upper panel). A 1.2-fold upregulation of PAFR transcription was observed with the lowest dose of treatment, and the upregulation was more than 3.2-fold higher at the highest treatment dose. With increasing doses of CDDP, we also observed up to 3.4- and 4.0-fold increases in PAFR protein levels in SKOV-3 and CAOV-3 cells, respectively. In a time-gradient assay (0--24 h) with 10 *μ*[M]{.smallcaps} of CDDP, we observed an upregulation of the PAFR mRNA and protein levels in both cell lines as early as 1 h after treatment ([Figure 1A and B](#fig1){ref-type="fig"}, lower panel). Expression of PAFR increased with exposure time and reached maximum levels at 24 h. These data show that the expression of PAFR in ovarian cancer cells is induced by exposure to the chemotherapeutic agent CDDP in a dose- and time-dependent manner.

Nuclear factor-kappa B and HIF-1***α*** are major players in the CDDP-induced expression of PAFR
------------------------------------------------------------------------------------------------

Studies have reported that CDDP treatment modulates the activity of several transcription factors, including NF-*κ*B ([@bib22]) and HIF-1*α* ([@bib28]). These transcription factors are also, reportedly, involved in the PAFR function in other cancer types ([@bib14]). To investigate whether NF-*κ*B and HIF-1*α* mediate CDDP-induced upregulation of PAFR, we observed the change in their expression and subcellular localisation following CDDP treatment. The results demonstrate that the CDDP treatment of SKOV-3 and CAOV-3 cells causes a time-dependent increase in the nuclear levels of NF-*κ*B/p65 ([Figure 2A and B](#fig2){ref-type="fig"}, upper panel) with a corresponding decrease in the cytoplasmic levels ([Figure 2A and B](#fig2){ref-type="fig"}, middle panel). Furthermore, after CDDP treatment, we also detected an increase in nuclear levels of HIF-1*α* ([Figure 2A and B](#fig2){ref-type="fig"}, upper panel) as well as an increase in the cytoplamic fractions of ovarian cancer cell lysates ([Figure 2A and B](#fig2){ref-type="fig"}, middle panel). However, we did not observe a change in total NF-*κ*B and HIF-1*α* levels in whole cell lysates ([Figure 2A and B](#fig2){ref-type="fig"}, lower panel). As shown in [Figure 2C](#fig2){ref-type="fig"}, immunofluorescence localisation of NF-*κ*B and HIF-1*α* in SKOV-3 cells further confirmed that CDDP treatment induces nuclear accumulation of NF-*κ*B and HIF-1*α*. We next investigated the role of NF-*κ*B and HIF-1*α* in the CDDP-induced upregulation of PAFR. Using RNA interference, we silenced the expression of NF-*κ*B and HIF-1*α* in the SKOV-3 and CAOV-3 cells prior to treatment with CDDP. Our results show that siRNAs targeting NF-*κ*B and HIF-1*α* were able to effectively silence the expression of these transcription factors, leading to their reduced nuclear accumulation. In addition, our data show that suppression of NF-*κ*B or HIF-1*α* results in the abrogation of CDDP-induced PAFR expression, although the effect of NF-*κ*B silencing on PAFR expression ([Figure 3A and B](#fig3){ref-type="fig"}) is more potent compared with HIF-1*α* silencing ([Figure 3C and D](#fig3){ref-type="fig"}). To further analyse the effect of NF-*κ*B and HIF-1*α* inhibition on CDDP-induced apoptosis, we performed Annexin V/PI analysis ([Figure 3E and F](#fig3){ref-type="fig"}), our data show that the suppression of NF-*κ*B and HIF-1*α* led to an increase in cell apoptosis when cells were exposed to CDDP compared with CDDP alone. Together, these data demonstrate the role of NF-*κ*B and HIF-1*α* in CDDP-induced PAFR upregulation.

Suppression of PAFR with WEB2086 or depletion after siRNA silencing significantly enhances the CDDP sensitivity of ovarian cancer cells
---------------------------------------------------------------------------------------------------------------------------------------

To investigate the role of upregulated PAFR in the response of ovarian cancer cells to CDDP, SKOV-3 and CAOV-3 cells were pretreated with the PAFR small-molecular antagonist WEB2086 before exposure to CDDP (10 *μ*[M]{.smallcaps}). As shown in [Figure 4A](#fig4){ref-type="fig"}, PAFR inhibition by WEB2086 enhanced cell death in both ovarian cancer cell lines after CDDP treatment. When PAF was added to the cell culture, there was a significant decrease in cell death, however, there was a clear increase in cell death when cells were exposed to CDDP and WEB2086, compared with CDDP alone. To further analyse the effect of PAFR inhibition on CDDP-induced apoptosis, we performed an Annexin V/PI analysis ([Figure 4B](#fig4){ref-type="fig"}). The results show that there was an increase in cell apoptosis when the cells were exposed to CDDP and WEB2086 compared with CDDP alone. Furthermore, through RNA interference, we suppressed the expression of PAFR in SKOV-3 and CAOV-3 cells before treatment with CDDP. Our data indicate that PAFR-targeted siRNAs were able to effectively silence PAFR expression and that the suppression of PAFR led to an increase in cell apoptosis when cells were exposed to CDDP compared with CDDP alone ([Figure 4C](#fig4){ref-type="fig"}). As shown in [Figure 4C](#fig4){ref-type="fig"}, the apoptosis results were confirmed by a Western blot analysis. Both PAFR-targeted siRNA and CDDP were able to induce the cleavage of 113-kDa poly-ADP-ribose polymerase (PARP) to the 89-kDa fragment and induce cleaved caspase-3 in SKOV-3 and CAOV-3 cells, and the combination of two agents was accompanied by increased expression of cleaved PARP and caspase-3. Together, our data show that suppression of PAFR significantly enhanced the CDDP sensitivity of ovarian cancer cells.

Phosphoinositide 3-kinase and ERK lie downstream from activated PAFR in CDDP-treated ovarian cancer cells
---------------------------------------------------------------------------------------------------------

We next investigated the downstream signalling pathway of activated PAFR in CDDP-treated ovarian cancer cells. The activation of the PI3K and ERK signal pathways is a common cause of cell apoptosis or survival ([@bib30]). Additionally, the PAF--PAFR signalling axis has been shown to activate AKT and ERK in several types of cancer cells ([@bib1]; [@bib13]). Therefore, we next examined whether PI3K and ERK might function downstream of PAFR in CDDP-treated ovarian cancer cells. In a time-course assay (0--24 h) with a 10 *μ*[M]{.smallcaps} CDDP treatment, we observed maximum activation of P70S6K/Akt/Erk phosphorylation at 12 h in the SOKV-3 cells and at 6 h in the CAOV-3 cells ([Figure 5A and C](#fig5){ref-type="fig"}). Furthermore, when PAF was added to the cell culture, there was a marked increase in the amount of P70S6K/Akt/Erk phosphorylation in both cells ([Figure 5A and C](#fig5){ref-type="fig"}). To investigate whether the activation of the PI3K and ERK pathways is PAFR-dependent, WEB2086 was added to the culture medium 1 h before CDDP and/or PAF stimulation. In both the SKOV-3 and CAOV-3 cells, we observed a decrease in the phosphorylation of P70S6K/Akt/Erk as we increased the concentration of WEB2086 (25--100 *μ*[M]{.smallcaps}) ([Figure 5B and D](#fig5){ref-type="fig"}). Together, our data suggest that PI3K and ERK activation occurs downstream of the PAF--PAFR signalling axis in CDDP-treated ovarian cancer cells.

The blockade of the PI3K and ERK pathways sensitises ovarian cancer cells to CDDP
---------------------------------------------------------------------------------

To evaluate whether PAFR-dependent PI3K and ERK activation is involved in the modulation of the ovarian cancer cell responses to CDDP, we treated the SKOV-3 and CAOV-3 cells with specific pharmacological inhibitors of PI3K (LY294002) and ERK (PD98059) prior to stimulation with PAF and CDDP. Immunoblot analyses demonstrated effective and specific inhibition of activated PAFR-induced phosphorylation of P70S6K/Akt/Erk in both of the CDDP-treated cell lines ([Figure 6A](#fig6){ref-type="fig"}). The inhibition of growth and the proportion of apoptosis were evaluated by a CCK-8 assay ([Figure 6B](#fig6){ref-type="fig"}) and a flow cytometry assay ([Figure 6C](#fig6){ref-type="fig"}), respectively. Both the inhibition of growth and the proportion of apoptosis were significantly higher in the cells treated with a co-administration of PAF, CDDP, PD98059 and LY294002 compared with the cells treated with PAF-CDDP alone or PAF-CDDP plus either agent. Meanwhile, treatment with PD98059 or LY294002 alone only slightly affected cell viability and apoptosis in the SKOV-3 and CAOV-3 cells. Together, these data indicate that the PI3K and ERK pathways downstream of activated PAFR are associated with CDDP responses in ovarian cancer cells.

Inhibition of PAFR significantly sensitises CDDP therapy in an ovarian cancer model
-----------------------------------------------------------------------------------

To bolster our *in vitro* findings and to determine whether PAFR could be an effective therapeutic target for ovarian cancer, we examined the effects of GB in an ovarian cancer animal model by intraperitoneally implanting SKOV-3-luc cells into mice. Ginkgolide B is the primary active component of Ginkgo biloba extracts and has proven to be an effective antagonist against PAFR. The fluorescence intensity (ROI) values represented the tumour volume in each group, and the ROI curves showed a slight decrease in tumour volume in mice treated with CDDP or GB in comparison with the control group. However, there was significant inhibition of tumour growth in the group subjected to the combination therapy (CDDP and GB) ([Figure 7A and B](#fig7){ref-type="fig"}). This group also showed the lightest tumour tissues ([Figure 7C](#fig7){ref-type="fig"}). Furthermore, to detect the concentration of PAF, we collected the tail vein blood of the nu/nu mice in each group at the following time points: before implanting the SKOV-3-luc cells, before the therapy treatment and 2 weeks after the treatment. As shown in [Figure 7D](#fig7){ref-type="fig"}, the serum PAF values were elevated after the i.p. ovarian cancer cells injection but were not altered by the other treatments in all four groups. Immunohistochemical staining on the ovarian cancer tissues of four treatment groups revealed that PAFR protein expression was significantly increased after 3 weeks of CDDP treatment. The inhibition of PAFR expression was observed when the combination treatment with GB and CDDP was executed ([Figure 7E](#fig7){ref-type="fig"}). Together, these data suggest that the combination therapy with GB and CDDP was effective in reducing tumour progression.

Discussion
==========

The PAF/PAFR signalling axis has emerged as an important determinant of aggressive phenotypes in several malignancies ([@bib31]; [@bib24]). Our earlier data demonstrated that GB, a specific antagonist of PAFR, had an additive effect with the most commonly used chemotherapy agent, CDDP, and exhibited significantly less cytotoxicity than CDDP ([@bib12]). The present study provides additional support for the functional significance of the PAF/PAFR signalling axis as a resistance mechanism by demonstrating an upregulation of PAFR in response to CDDP treatment of ovarian cancer cells. Transcriptional upregulation of PAFR is facilitated by the nuclear accumulation of the NF-*κ*B and HIF-1*α* transcription factors. Selective PAFR suppression with WEB2086 or RNA interference-mediated knockdown results in the enhancement of CDDP sensitivity of the ovarian cancer cells. In addition, we found that downstream of PAF/PAFR, the PI3K and ERK signalling pathways are two of the potential mechanisms for the regulation of CDDP responses. Finally, our *in vivo* ovarian cancer model results showed that, in the presence of CDDP, the PAFR-specific antagonist GB, inhibited tumour growth, thus demonstrating the therapeutic effect of PAFR suppression. Together, our findings suggest that CDDP-induced PAFR upregulation modulates the CDDP sensitivity of ovarian cancer cells.

Expression of PAFR is elevated in non-mucinous types of ovarian cancer tissues and cells, which suggests that it has a role in the pathogenesis and progression of ovarian cancer. The sole ligand of PAFR, PAF, is secreted by many different cell types, including endothelial, stromal and inflammatory cells. The PAF is also secreted by many different tumour cells ([@bib17]; [@bib4]), thus indicating an important role for PAF/PAFR signalling in ovarian cancer progression. In addition, it has been shown that PAF/PAFR significantly promotes ovarian cancer proliferation and invasion. In the present study, we observed that CDDP treatment led to a dose- and time-dependent increase in PAFR expression. This observation provides additional support for our earlier findings, which showed that, GB may sensitise ovarian cancer cells to cisplatin. Our data suggest that induction of PAFR upon CDDP treatment could be a counter defense mechanism of ovarian cancer cell resistance to apoptosis by promotion of PAF/PAFR-induced cell survival pathways.

Our data show direct roles of NF-*κ*B/p65 and HIF-1*α* in the CDDP-induced upregulation of PAFR expression in ovarian cancer cells. Activation of NF-*κ*B/p65 and HIF-1*α* transcription activity by chemotherapy agents has previously been reported and has been shown to be essential for oncogenic transformation ([@bib18]; [@bib27]). Our data reveal that the effect of NF-*κ*B silencing on PAFR expression is more potent compared with HIF-1*α* silencing, suggesting that there is a possibility that CDDP-induced HIF-1*α* upregulation is NF-*κ*B/p65 dependent. This finding is supported by published data on other cancers in which NF-*κ*B and HIF-1*α* have had roles in CXCR4 (a G-protein coupled receptor) expression ([@bib21]). However, as transcription factors, NF-*κ*B and HIF-1*α* can interact with a variety of proteins; thus, we need to further analyse the mechanism behind the CDDP induction of increased PAFR expression.

The PAF--PAFR-mediated stimulation of the downstream phosphorylation of multiple proteins has been reported in other non-cancerous types of cells ([@bib20]) and involve many types of protein kinases including mitogen-activated protein kinase, protein kinase C and PI3K, among others ([@bib11]). Our previous study demonstrated that PAF/PAFR, through FAK, PI3K and MMP2, initiates multiple downstream signal pathways involved in ovarian cancer cell proliferation and invasion. In addition, the PI3K and ERK pathways, which mediate critical signals for cell proliferation, survival and differentiation ([@bib26]), are activated in various types of cancer. Several other studies have also shown that the constitutive or induced activation of the PI3K and ERK pathways has been associated with the chemoresistance of cancer cells ([@bib29]; [@bib9]). In the present study, our data show that as CDDP induced the upregulation of PAFR, there was a concomitant marked increase in PI3K/ERK phosphorylation in the ovarian cancer cells exposed to CDDP and PAF. We also observed that the LY294002 and PD98059 treatments sensitised ovarian cancer cells to CDDP. The findings suggest that induction of PAFR by CDDP may lead to the potentiation of the survival pathways downstream of PAFR and thus enable cancer cells to counter CDDP-induced cytotoxicity. Previously, it was shown that PAF simultaneously induced the phosphorylation of multiple proteins including EGFR. The EGFR has been described as an important regulatory effector that is capable of stimulating PI3K/ERK signalling. Thus, we speculate that PAF/PAFR may induce EGFR transactivation, thereby mediating PI3K/ERK activation. A detailed mechanism for the crosstalk between PAFR and EGFR has not yet been fully characterised.

Furthermore, in the SKOV-3-luc ovarian cancer xenograft models, we observed that the PAFR protein expression was significantly increased in the CDDP treatment group while reduced in the CDDP plus GB treatment group, suggesting that the PAFR expression is closely related to tumour progression. In addition, the concentrations of mouse serum PAF were significantly elevated in all four groups after the ovarian cancer cell injection, but the values were not altered during the treatments of the four groups. However, the PAFR-specific antagonist GB could effectively inhibit tumour growth, suggesting that when PAFR was blocked, PAF was rendered ineffective and that PAFR might have an important role in modulating the CDDP sensitivity of ovarian cancer cells.

Our findings have thus revealed a previously unrecognised role of PAFR in modulating the CDDP sensitivity of ovarian cancer cells. Our results contribute to a better understanding of the molecular mechanisms of chemotherapy responses and provide a potential target for the development of novel combination therapy.
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![**Cisplatin induces increased PAFR expression in human ovarian cancer cells.** Ovarian cancer cells were treated with different doses (0--60 *μ*[M]{.smallcaps}) of cisplatin (CDDP) for 24 h (**A** and **B**, upper panels) or with a constant dose (10 *μ*[M]{.smallcaps}) of CDDP for different time intervals as indicated (**A** and **B**, lower panels). Total RNA and protein were extracted and analysed for PAFR expression by real-time PCR and immunoblot analysis, respectively. 18 s rRNA (realtime PCR) and *β*-actin (immunoblot) were used as internal controls. The data show that CDDP induces a dose- and time-dependent expression of PAFR levels as a transcript and as a protein. Bars represent the average of the triplicates±s.d.; \* (*P*\<0.05) and \*\* (*P*\<0.01) indicate a statistically significant difference compared with the untreated control.](bjc2014323f1){#fig1}

![**Treatment with CDDP enhances the nuclear localisation of NF-*κ*B/p65 and HIF-1*α*.** The SKOV-3 (**A**) and CAOV-3 (**B**) cells were treated with CDDP (10 *μ*[M]{.smallcaps}) at different time intervals (0--24 h). Thereafter, nuclear, cytoplasmic and total extracts were prepared and the expression and localisation of NF-*κ*B/p65 and HIF-1*α* were examined by immunoblot analysis. Histone H3 (for the nuclear fraction), *α*-tubulin (for the cytoplasmic fraction) and *β*-actin (for the total fraction) were used as loading controls. (**C**) The localisation of NF-*κ*B/p65 and HIF-1*α* in SKOV-3 cells with or without 10 μ[M]{.smallcaps} CDDP for 12 h treatment were analysed using immunofluorescence. The data indicate increased levels of NF-*κ*B/p65 and HIF-1*α* in the nuclei of the ovarian cancer cells treated with CDDP.](bjc2014323f2){#fig2}

![**The involvement of NF-*κ*B/p65 and HIF-1*α* in CDDP-induced PAFR expression in ovarian cancer cells.** Sub-confluent ovarian cancer cells were transiently transfected with a negative-control (NC) or siRNAs targeting either NF-*κ*B/p65 (**A** and **B**) or HIF-1*α* (**C** and **D**). Following 48 h of transfection, the NF-*κ*B/p65 and HIF-1*α* cells were treated with CDDP (10 *μ*[M]{.smallcaps}) for the next 12 h, and the PAFR cells were treated with CDDP (10 *μ*[M]{.smallcaps}) for the next 24 h. Nuclear and total proteins were isolated and subjected to immunoblot analysis to assess the expression of NF-*κ*B/p65, HIF-1*α* and PAFR. Histone H3 and *β*-actin were used as loading controls for the nuclear and total proteins, respectively. (**E** and **F**) Following 48 h of transfection, cells were treated with CDDP (10 *μ*[M]{.smallcaps}) for the next 12 h. Cell apoptosis was assessed by flow cytometric analysis. The data indicate that specific silencing of NF-*κ*B/p65 and HIF-1*α* enhance the sensitivity of CDDP and clearly demonstrate that CDDP-induced PAFR expression is mediated through the additive action of NF-*κ*B/p65 and HIF-1*α* in ovarian cancer cells.](bjc2014323f3){#fig3}

![**PAFR suppression with a pharmacological inhibitor or siRNA knockdown enhances the CDDP sensitivity of ovarian cancer cells.** The SKOV-3 and CAOV-3 cells were pretreated with the PAFR-antagonist WEB2086 (50 or 100 *μ*[M]{.smallcaps}) and then treated with CDDP (10 *μ*[M]{.smallcaps}) for 24 h in the presence or absence of PAF. Cell viability was assayed using a CCK-8 assay (**A**), and cell apoptosis was determined by AnnexinV/PI flow cytometric analysis (**B**). Both cell lines were transfected with a negative-control (NC) or PAFR-targeted siRNAs. Following 48 h of transfection, cells were treated with CDDP (10 *μ*[M]{.smallcaps}) for 24 h. Cell apoptosis was assessed by flow cytometric analysis (**C**). Western blotting analysis of PARP and caspase-3 cleavage following treatment with PAFR-targeted siRNA or with CDDP in both cell lines (**C**). Western blotting of *β*-actin is included as a loading control. The data indicate that WEB2086 and si-PAFR significantly enhance the CDDP sensitivity of ovarian cancer cells. Bars represent the average of the triplicates ±s.d.; \* (*P*\<0.05) and \*\* (*P*\<0.01) indicate a statistically significant difference compared with the untreated control. The data are representative of three independent experiments.](bjc2014323f4){#fig4}

![**The PI3K and ERK signalling lies downstream of activated PAFR in CDDP-treated ovarian cancer cells.** SKOV-3 (**A**) and CAOV-3 (**C**) cells were treated with CDDP (10 *μ*[M]{.smallcaps}) at different time intervals (0--24 h). Meanwhile, CDDP-treated cells at every point in time were stimulated with or without PAF (100 n[M]{.smallcaps}). Thereafter, total extracts were prepared and the phosphorylation of P70S6K/Akt/Erk was examined by immunoblot analysis. Both cell lines were pretreated with different doses of PAFR-antagonist WEB2086 (25--100 *μ*[M]{.smallcaps}) for 1 h before stimulation with PAF (100 n[M]{.smallcaps}) and CDDP (10 *μ*[M]{.smallcaps}) for 24 h (**B** and **D**). Total proteins were extracted, and the phosphorylation of P70S6K/Akt/Erk was examined by immunoblot analysis. *β*-actin was used as a loading control. The data show that p-PI3K/Akt/Erk was activated by PAFR in CDDP-treated cells and that the activation was PAFR-dependent. There was no different expression of total-P70S6K, total-Akt and total-Erk in each group (data not shown).](bjc2014323f5){#fig5}

![**The effect of the PI3K and ERK inhibitors on cell viability and apoptosis in CDDP-treated and PAFR-activated ovarian cancer cells.** (**A**) SKOV-3 and CAOV-3 cells were pretreated with PD98059 (20 *μ*[M]{.smallcaps}) and/or LY294002 (20 *μ*[M]{.smallcaps}) for 1 h before exposure to PAF (100 n[M]{.smallcaps}) and CDDP (10 *μ*[M]{.smallcaps}) for 24 h. Total protein was extracted and analysed for phosphorylation and P70S6K/Akt/Erk expression by immunoblot analysis. *β*-actin was used in the immunoblot as an internal control. (**B**) SKOV-3 and CAOV-3 cells were pretreated with PD98059 and lY294002 before PAF and CDDP treatment for 24 h. Viable cells were detected using a CCK-8 assay. (**C**) The proportion of cell apoptosis in both cell lines was assessed by flow cytometric analysis after treatment for 24 h with the indicated reagents. Bars represent the means ±s.d.;\* (*P*\<0.05) and \*\* (*P*\<0.01) indicate a statistically significant difference compared with the untreated control. The data are representative of three independent experiments. There was no different expression of total-P70S6K, total-Akt and total-Erk in each group (data not shown).](bjc2014323f6){#fig6}

![**Inhibition of PAFR significantly sensitises CDDP therapy in an ovarian cancer model.** (**A**) The representative *in vivo* imaging picture of the four groups of nude mice with peritoneal ovarian cancer. SKOV-3-luc cells were intraperitoneally injected into mice and the ROI was determined. (**B**) The ROI values represented the tumour size in each group as measured by a luciferin imaging system every 3 days. (**C**) Boxplots showing the tumour weight in four groups at the end of therapy. (**D**) The concentrations of mouse serum PAF were determined in each of the four groups before and after treatment with the different drugstore combinations. (**E**) Protein expression of PAFR in ovarian cancer tissues of four groups by immunohistochemistry (IHC). After 3 weeks of CDDP treatment, the PAFR expression was increased significantly (IHC, 10 × , \**P*\>0.05, \*\**P*\<0.05, \*\*\**P*\<0.01). CDDP, CDDP treatment group; DMSO, DMSO treatment group; GB, GB treatment group; GB+CDDP, GB+CDDP treatment group.](bjc2014323f7){#fig7}
